|1.||Brüning, Ansgar: 10 articles (12/2013 - 12/2008)|
|2.||Friese, Klaus: 7 articles (12/2013 - 12/2008)|
|3.||Maity, Amit: 5 articles (05/2015 - 09/2006)|
|4.||Chow, Warren A: 5 articles (01/2015 - 09/2006)|
|5.||Hahn, Stephen M: 5 articles (01/2014 - 09/2006)|
|6.||Rahmeh, Martina: 5 articles (12/2013 - 12/2008)|
|7.||Schönthal, Axel H: 5 articles (12/2012 - 11/2007)|
|8.||Chen, Thomas C: 5 articles (12/2012 - 01/2007)|
|9.||Guan, Min: 4 articles (01/2015 - 04/2011)|
|10.||Dennis, Phillip A: 4 articles (09/2014 - 09/2007)|
|1.||HIV Infections (HIV Infection)
09/01/2013 - "Nelfinavir is being studied for the prevention and treatment of a wide range of malignancies in persons with and without HIV infection. "
04/01/2006 - "A review of nelfinavir for the treatment of HIV infection."
01/01/2005 - "Nelfinavir also has a role in the management of pregnant patients as well as paediatric patients with HIV infection."
01/01/2005 - "Nelfinavir may be used in the treatment of adults, adolescents and children aged >or=2 years with HIV infection. "
01/01/2005 - "Nelfinavir: a review of its use in the management of HIV infection."
|2.||Ovarian Neoplasms (Ovarian Cancer)
10/01/2010 - "We have previously demonstrated induction of apoptosis by nelfinavir even in chemo-resistant ovarian cancer cells. "
02/01/2009 - "Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis."
12/26/2008 - "We conclude that nelfinavir, an already approved drug, is a highly efficient agent against ovarian cancer cells and could sensitize ovarian cancer cells to TRAIL treatment, either therapeutically applied or endogenously produced by cells of the immune system."
12/26/2008 - "In vitro, at concentrations used to induce cell death in ovarian cancer cells, nelfinavir had no effect on the cellular viability of fibroblasts or peripheral blood mononuclear leukocytes. "
12/26/2008 - "Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells."
06/01/2010 - "Furthermore, anti-microbial effects of nelfinavir have been described, including an efficacy against malaria, tuberculosis, and SARS. "
05/01/2015 - "The HIV protease inhibitor, nelfinavir, primarily used for the treatment of HIV infections, has later been shown to be effective in various infectious diseases including malaria. "
01/01/2010 - "HIV protease inhibitors, indinavir or nelfinavir, are important antiretroviral drugs and artemisinin is central to malaria treatment. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
10/01/2005 - "Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403."
09/01/2003 - "Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377."
11/01/2015 - "Nelfinavir mesylate (NFV) is an anti-viral drug, used in the treatment of Acquired Immunodeficiency Syndrome (AIDS). "
07/01/2010 - "HIV-1-infected children (n = 152) from Pediatric AIDS Clinical Trial Group 366 or 377 receiving nelfinavir as a component of HAART were evaluated. "
12/01/2005 - "Adult AIDS Clinical Trials Group study 384 randomized antiretroviral-naive subjects to receive efavirenz and/or nelfinavir plus 2 nucleoside analogues, with follow-up lasting up to 3 years. "
06/04/2004 - "Experiments with various timings of drug addition revealed that nelfinavir exerted its effect not at the entry step, but at the post-entry step of SARS-CoV infection. "
06/04/2004 - "Nelfinavir inhibited the cytopathic effect induced by SARS-CoV infection. "
01/01/1996 - "AG1343 has potent antiviral activity (95% effective dose = 0.04 microgram/ml) against a number of HIV-1 strains in acute and chronic models of infection. "
09/01/2013 - "Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells."
07/24/2002 - "Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection."
|5.||Protease Inhibitors (Protease Inhibitor)
|6.||HIV Protease Inhibitors
|7.||sorafenib (BAY 43-9006)
|8.||Reverse Transcriptase Inhibitors
|1.||Highly Active Antiretroviral Therapy (HAART)
|3.||Heterologous Transplantation (Xenotransplantation)